Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Sep 8;7:10981. doi: 10.1038/s41598-017-11496-3

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2017

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Identification of 5-LO derivative metabolites in BMDMs after exogenous AA stimulation and treatments. BMDMs were treated with IFN-γ (100 ng/mL) (M1), IL-4 + IL-13 (10 ng/mL) (M2) for 24 h, or only adhered (M0). (A) cAMP in BMDMs pretreated or not with indomethacin (10 mM) for 30 min, or EP2 antagonist (AH6809, 1 mM); with or without subsequent ionophore A23187 (0.5 μM) stimulation for 9 min (two independent experiments in duplicate, n = 2). Lipids in cell culture supernatants were identified and quantified for BMDMs (M0) pretreated with or without indomethacin (10 mM) for 30 min, or diamide (1000 or 500 μM) for 10 min; with or without subsequent ionophore A23187 (0.5 μM) stimulation for 15 min and/or zymosan (10 μg/mL) for 1.5 h diluted in DMEM. In addition, BMDMs were incubated with or without AA (40 μM) for 10 min before treatment and stimulation. (B) HPLC-MS/MS (MRM^HR) for eicosanoids: LTB₄, LTD₄, 5-HETE, and 5-oxo-ETE. (C) PCA with Log autoscaling on HPLC-TOF-MS polar lipids. PCA score discrimination of BMDM total polar lipids with or without AA-stimulation and/or ionophore A23187 post-stimulation (n = 3 from each depot, analysed in duplicate). (D) HPLC-MS/MS (MRM^HR) for eicosanoids: LTB₄, 5-HETE, and 5-oxo-ETE on AA-stimulated BMDMs with or without treatment, and post-stimulation with ionophore A23187 (n = 3, analysed in duplicate). (A,B, and D) The results are presented as the means ± s.e.m. Differences are considered significant when p < 0.05, *comparing stimulated-BMDMs versus non-stimulated; ^#treatment versus non-treated stimulated-BMDMs.